Objective: To investigate the anti-
inflammatory effect and its mechanism of (tetrame-)(thylpyrazine(TMP)) in patients with
acute coronary syndrome (ACS). Methods: Thirty-two patients were randomly divided into TMP group or routine
treatment control group. All patients received the same standard treatment. The patients in TMP group received TMP 3 mg/kg intravenous injection every 12 hours for 5 days. Plasma concentrations of C-reactive protein (CRP), serum amyloid A (SAA) and plasminogen activator (inhibitor-1) (PAI-1) were measured at baseline and after 5 days of therapy. Results: After 5 days treatment, both concentrations of CRP and SAA increased significantly in control group (all P<0.05), PCI-1 increased mildly. In TMP group, only SAA had a significant increase (P<0.05), the change of CRP was not (significant), and the concentration of PCI-1 increased mildly. The absolute increases of CRP, SAA, and (PAI-1) were significantly less in TMP group than that in control group (all P<0.05). Conclusion: TMP has an anti-
inflammatory and profibrinolytic effect in patients with ACS. These effects may contribute to the (clinical) benefits of TMP in ischemic heart disease.